Geron Corp GERN shares are trading lower in Wednesday's after-hours session after the company announced a proposed public offering.
What To Know: Geron said it intends to sell $175 million of its common stock in an underwritten public offering. The company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of its common stock.
In Wednesday's regular trading session, Geron shares soared above $4, before pulling back and closing up 32.9% at $3.19 after the company announced positive top-line results from a rare blood cancer trial.
Related Link: Geron Stock Surges After Encouraging Data From Rare Blood Cancer Trial
Geron is a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies.
See Also: Why Vyant Bio Shares Are Soaring After Hours
GERN Price Action: Geron shares are down 11.3% in after-hours at $2.83 at the time of publication, according to Benzinga Pro.
Photo: fernando zhiminaicela from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
